{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE324nnn/GSE324334/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE324334"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Long-term Antigen Reduction is Insufficient to Cure Hepatitis B Virus in Mice","description":"Chronic hepatitis B virus (HBV) infection remains a major cause of mortality, and curative treatments are still lacking. This study investigated whether prolonged suppression of HBV antigens could restore HBV-specific immune responses and support therapeutic vaccination. HBV-carrier mice were treated for up to eight months with liver-directed siRNAs or shRNAs targeting all HBV transcripts. Although viral antigens declined initially, a threshold was reached after four months, and extended suppression alone did not restore T-cell immunity; viral replication rebounded after treatment stopped. However, combining antigen suppression with the therapeutic vaccine TherVacB reconstituted antiviral T-cell responses and achieved sustained HBV control. Longer siRNA pretreatment enhanced interferon signaling and improved vaccine-induced immunity, highlighting the need for combined antiviral suppression and immune stimulation.","dates":{"publication":"2026/09/02"},"accession":"GSE324334","cross_references":{"GSM":["GSM9573822","GSM9573821","GSM9573831","GSM9573820","GSM9573830","GSM9573826","GSM9573825","GSM9573824","GSM9573823","GSM9573819","GSM9573829","GSM9573818","GSM9573817","GSM9573828","GSM9573827","GSM9573816"],"GPL":["34328"],"GSE":["324334"],"taxon":["Mus musculus"],"PMID":["[42379305]"]}}